Нефрэктомия и адъювантная иммунотерапия интерлейкином 2 при распространенной почечно-клеточной карциноме

1. Петров С.В., Райхлин Н.Т. Руководство по иммуногистохимической диагностике опухолей. — Казань, 2004. — С.93—100.

2. Jemal A., Thomas A., Murray T. et al. Cancer statistics 2002 // Cancer J. Clin. — 2002; 52:23—47.

3. Носов Д.А., Тюляндин С.А. Диссеминированный рак почки: факторы прогноза, лечение и перспективы // Онкоурология. — 2005. — №1. — С.26.

4. Igarashi T., Tobe T., Nakatsu H.O. et al. The impact of a 4 cm cutoff point for stratification of TINOMO renal cell carcinoma after radical nephrectomy // J. Urol. — 2001; 165:1103—1106.

5. Figlin R.A. Renal cell carcinoma: management of advanced disease. // J. Urol. — 1999; 161:381—386.

6. Mickisch G.H., Garin A., van Poppel H. et al. For the European Organisation for Research and Treatment of Cancer. Radical nephrectomy plus interferon alfa based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: a randomised trial // Lancet. — 2001; 358:966—970.

7. Pantuck A.J., Belldegrun A.S., Figlin R.A. Nephrectomy and interleukin-2 for metasiatic renal-cell carcinoma // N. Engl. J. Med. — 2001; 345:1711—1712.

8. Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer // N. Engl. J. Med. — 2001; 345:1655—1659.

9. Atzpodien J., Schmitt E., Gertenbach U. et al. Adjuvant treatment with interleukin-2 and interferon-alpha2a based chemoimmunotherapy in renal cell carcinoma post tumor nephrectomy: Results of a prospectively randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) // Brit. J. Cancer. — 2005; 92: 843—846.

10. Gelb A.B. Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) // Cancer. — 1997; 80:981—986.

11. Javidan J., Strieker H.J., Tamboli P. et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma // J. Urol. — 1999; 162:1277—1281.

12. Mani S., Todd M.B., Katz K. et al. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. // J. Urol. — 1995; 154:35—40.

13. Motzer R.J., Mazumdar M., Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. // J. Clin. Oncol. — 1999; 17:2530—2540.

14. Papadopoulos I., Rudolph P., WeichertJacobsen K. et al. Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine // Urology. — 1996; 48:373—378.

15. Srigley J.R., Hutter R.V., Gelb A.B. et al. Current prognostic factors — renal cell carcinoma: Workgroup # 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) // Cancer. — 1997; 80:994—996.

16. Tsui K.H., Shvarts O., Smith R.B. et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria // J. Urol. — 2000; 163:1090—1095.

17. Zisman A., Pantuck A.J., Dorey F. et al. Mathematical model to predict individual survival for patients with renal cell carcinoma // J. Clin. Oncol. — 2002; 20:1368—1374.

18. Tsui K.H., Shvarts O., Smith R.B. et al. Renal cell carcinoma: prognostic significance of incidentally detected tumors // J. Urol. — 2000; 163:426—430.

19. Leibovich В.С., Han K., Bui M.H.T. et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. // Cancer. — 2003; 98:2566—2575.

20. Журавлев В.Н., Зырянов А.В., Бершадский Я.В. и соавт. Гуморальные факторы прогнозирования результатов лечения метастатического почечноклеточного рака у больных после радикальной нефрэктомии // Юбилейный вестник СООД. — (в печати).

21. Elson P.J., Witte R.S., Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma // Cancer. Res. — 1988; 48(24 Pt l):7310—7313.

22. Targonski P.V., Frank W., Stuhldreher D. et al. Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes and metastases Stage 1 and Stage 2 patients // J. Urol. — 1994; 152(5 Pt 1):1389—1392.

23. Frank I., Blute M.L., Cheville J.C. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score // J. Urol. — 2002; 168:2395—2400.

24. Frank I., Blute M.L., Weaver A.L. et al. TNM staging alone is inadequate for predicting cancer-specific survival following radical nephrectomy for unilateral renal cell carcinoma // J. Urol. — 2001; 165:768A.

25. Schafhauser W., Ebert A., Brod J. et al. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy // Anticancer Res. — 1999; 19:1573—1578.

26. Vasselli J.R., Yang J.C., Linehan W.M. et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma // J. Urol. — 2001; 166:68—72.

27. Tarek M., Rony A.J., Wood L. et al. Validation and extension of Memorial Sloan Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. The Third International Kidney Cancer Symposium 2004. — Р. 251—254.

28. Ljungberg B., Landberg G., Alamdari F.L. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy // Scand. J. Urol. Nephrol. — 2000; 34:246—251.

29. Maldazys J.D., deKemion J.B. Prognostic factors in metastatic renal carcinoma // J. Urol. — 1986; 136:376—379.

30. Jacobs E.L., Clare-Salzler M.J., Chopra I.J. et al. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha // J. Immunother. — 1991; 10:448—455.

31. Vassilopoulou-Sellin R., Sella A., Dexeus F.H. et al. Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2. Horm. Metab. Res. — 1992; 24:434—438.

32. Weijl N.I., Van der Harst D., Brand A. et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment // J. Clin. Oncol. — 1993; 11:1376—1383.

33. Amin M.B., Tamboli P., Javidan J. et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases // Am. J. Surg. Pathol. — 2002; 26:281—291.

34. Kanamaru H., Sasaki M., Miwa Y. et al. Prognostic value of sarcomatoid histology and volume-weighted mean nuclear volume in renal cell carcinoma // BJU Int. — 1999; 83:222—226.

35. Moch H., Gasser T., Amin M.B. et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. // Cancer. — 2000; 89:604—614.

36. Haitel A., Wiener H.G., Migshitz B. et al. Proliferating cell nuclear antigen and MIB-1. An alternative to classic prognostic indicators in renal cell carcinomas? // Am. J. Clin. Pathol. — 1997; 107:229—235.

37. Morell-Quadreny I., Clar-Blanch F., Fennollosa-Enterna B. et al. Proliferating cell nuclear antigen (PCNA) as a prognostic factor in renal cell carcinoma. // Anticancer Res. — 1998; 18:677—682.

38. Jennigs S.B., Gnarra J.R., Walther M.M. et al. Renal cell carcinoma. Molecular genetics and clinical implications. // Surg. Oncol. Clin. North. Am. — 1995; 4:219—229.

39. Kovacs G. Molecular genetics and diagnosis of renal cell tumors. // Urologe. — 1999; 38:433—441.

40. Lam J.S., Belldegrun A.S., Figlin R.A. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy // Clinical Cancer Research. — 2004; 10:6304—6309.

41. Oda H., Nakatsuru Y., Ishikava T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas // Cancer. Res. — 1995; 55:658—662.

42. Motzer R.J., Bacik J., Murphy B.A. et al. Interferon alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma // J. Clin. Oncol. — 2002; 20:289—296.